HMG-CoA reductase inhibitors in chronic heart failure : Potential mechanisms of benefit and risk

• Published in: Drugs (New York, N.Y.) Vol. 66; no. 2; pp. 145 - 154
• Main Authors: LAUFS, Ulrich, CUSTODIS, Florian, BÖHM, Michael
• Format: Journal Article
• Language: English
• Published: Auckland Adis International 01.01.2006; Wolters Kluwer Health, Inc
• Subjects: Animals; Antioxidants - therapeutic use; Biological and medical sciences; Cardiology. Vascular system; Cardiovascular system; Cell Proliferation; Coronary Artery Disease - prevention & control; Endothelium, Vascular - metabolism; Heart; Heart Failure - drug therapy; Heart failure, cardiogenic pulmonary edema, cardiac enlargement; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Hypertrophy, Left Ventricular - prevention & control; Inflammation - prevention & control; Medical sciences; Miscellaneous; Neovascularization, Physiologic; Nitric Oxide - metabolism; Pharmacology. Drug treatments; Randomized Controlled Trials as Topic; Stem Cells - cytology; Human; Heart failure; Cardiovascular disease; Statin derivative; Review; Epidemiology; Chronic; Treatment; Heart disease; HMG-CoA reductase inhibitor; Risk factor; Mechanism of action; Antilipemic agent
• ISSN: 0012-6667; 1179-1950
• DOI: 10.2165/00003495-200666020-00002

HMG-CoA reductase inhibitors (statins) have been shown to reduce mortality and cardiovascular morbidity in patients with hyperlipidaemia and those with coronary artery disease. However, evidence for statin treatment in patients with chronic heart failure (CHF) remains a subject of debate. Patients with heart failure were generally excluded in the existing trials and a different patient population with a distinct pattern of morbidity and treatment was studied. In addition, no safety data are available for statins in patients with heart failure, where there are potential concerns about coenzyme Q10 depletion and excessive low-density lipoprotein reduction. This review summarises the clinical and preclinical evidence for potential beneficial effects of statins in CHF. In experimental systems, statins have been shown to improve cardiac function through antioxidative and anti-inflammatory action. Statins improve endothelial function, may reduce neurohormonal activation, and stimulate endothelial progenitor cells. Some of these effects occur independently of cholesterol lowering and can be explained by inhibition of isoprenylation of signal transducing proteins of the family of Rho guanosine triphosphatases. Two ongoing controlled randomised trials (CORONA [Controlled Rosuvastatin Multinational Study in Heart Failure] and GISSI-HF [Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico--Heart Failure]) will help us to assess whether the described beneficial effects of statins in heart failure outweigh the potential negative effects and translate into the reduction of clinical endpoints.